Find a Drug
Advanced Search

Professional

Megace

Side Effects & Drug Interactions
font size

SIDE EFFECTS

Clinical Adverse Events: Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing MEGACE Oral Suspension.

Adverse Events

% of Patients Reporting

 

Trial 1 (N= 236)

Trial 2 (N= 87)

Open Label Trial

Megestrol Acetate

mg/ day

Placebo 0

100

400

800

Placebo 0

800

1200

No. of Patients

N= 34

N= 68

N= 69

N= 65

N= 38

N= 49

N= 176

Diarrhea

15

13

8

15

8

6

10

Impotence

3

4

6

14

0

4

7

Rash

9

9

4

12

3

2

6

Flatulence

9

0

1

9

3

10

6

Hypertension

0

0

0

8

0

0

4

Asthenia

3

2

3

6

8

4

5

Insomnia

0

3

4

6

0

0

1

Nausea

9

4

0

5

3

4

5

Anemia

6

3

3

5

0

0

0

Fever

3

6

4

5

3

2

1

Libido Decreased

3

4

0

5

0

2

1

Dyspepsia

0

0

3

3

5

4

2

Hyperglycemia

3

0

6

3

0

0

3

Headache

6

10

1

3

3

0

3

Pain

6

0

0

2

5

6

4

Vomiting

9

3

0

2

3

6

4

Pneumonia

6

2

0

2

3

0

1

Urinary Freq.

0

0

1

2

5

2

1


 Adverse events which occurred in 1 to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow- up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.

Body as a Whole: abdominal pain, chest pain, infection, moniliasis and sarcoma

Cardiovascular System: cardiomyopathy and palpitation

Digestive System: constipation, dry mouth, hepatomegaly, increased salivation and oral moniliasis

Hemic and Lymphatic System: leukopenia

Metabolic and Nutritional: LDH increased, edema and peripheral edema

Nervous System: paresthesia, confusion, convulsion, depression, neuropathy, hypesthesia and abnormal thinking

Respiratory System: dyspnea, cough, pharyngitis and lung disorder

Skin and Appendages: alopecia, herpes, pruritus, vesiculobullous rash, sweating and skin disorder

Special Senses: amblyopia

Urogenital System: albuminuria, urinary incontinence, urinary tract infection and gynecomastia

Postmarketing: Postmarketing reports associated with MEGACE Oral Suspension included thromboembolic phenomena including thrombophlebitis, pulmonary embolism and glucose intolerance (see WARNINGS and PRECAUTIONS).

DRUG INTERACTIONS

Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or with rifabutin to warrant dosage adjustment when megesterol acetate is administered with these drugs. The effects of zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.

Brand Name: Megace
Generic Name: Megestrol Acetate

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Bookmark this page:


WebMD Daily

Get breaking medical news.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn

HIV Test for Early DetectionHIV Test for Early Detection
There is a test that may help detect the virus sooner, so patients can start treatment much faster. See more WebMD Videos »